Tagged with regulation,

Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…

India Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated opportunities for private players.   In theory, India’s states will be able to fine tune Modicare’s implementation to meet their…

Spain Teresa Chavarria Gimenez, director general of planning, research and training at the Ministry of Health of the Community of Madrid, highlights her role and the BioMad initiative as they look to position Madrid on the European and global biotech map.   We want to facilitate the collaboration of the public…

Egypt On Tuesday, February 12th, Pharmaboardroom attended a breakfast event hosted by the British Egyptian Business Association (BEBA) on competition law at the Cairo Semiramis Intercontinental Hotel. The theme for the event was competition law and its application in the Egyptian market, with the topic being introduced through a speech by…

France Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France.   We are still a very young company… and that means that we are still very much in the process of constructing…

Spain María Jesús Lamas, director and César Hernández García, head of medicines for human use at the Spanish Agency of Medicine and Health Products (AEMPS), discuss the challenges impacting the evaluation and analysis of products today. Furthermore, they give insights into why Spain is a leading global clinical trials destination and…

France The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is subject to mounting regulatory pressures meaning politics must play a key role. As we advance more and more in healthcare…

France On February 4 in Paris, Minister of Health and Solidarity Agnès Buzyn, Minister of Higher Education, Research and Innovation Frédérique Vidal, Secretary of State to the Minister of Economy and Finance Agnès Pannier-Runacher, and President of the Healthcare Industry Strategic Committee (CSF) and Chairman of the French Federation of Health…

India Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this article, he examines the benefit of the recent policy changes to price controls for innovative drugs in India.  Unlike many other countries, India controls prices of all drugs…

Malaysia After 61 years of single-party rule, the May 2018 electoral victory of the populist Pakatan Harapan (PH) coalition sent shockwaves through the Malaysian political landscape. This has been keenly felt within the healthcare sphere, where industry players are broadly supportive of PH’s plans to increase low-income Malaysians’ access to treatments…

India Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output and drug inspectors.    Improving the image of drug inspectors- will require investments in “infrastructure”. The key elements of this…

Egypt Egypt continues to struggle with fake drugs reaching the hands of patients as the suppliers of counterfeit medicines become more sophisticated by adding company logos to packaging.   The Egyptian police have launched large-scale surveillance campaigns aimed at “Bir Al-Salam factories” which are known for manufacturing these drugs that include multiple unknown…